Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Extended-release depot naltrexone in heroin-dependent patients
NL-OMON35900Phase 3Not yet recruiting
- Sponsor
- Amsterdam University Medical Center
- Start
- Oct 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label trial of naltrexone in opioid use disorder (OUD) and heroin addiction (2 arms), sponsored by Amsterdam University Medical Center. Primary endpoints: Brain function changes during XRNT treatment and Adverse effects on natural rewards. Planned start Oct 2012; status: not yet recruiting.
02
Drugs
naltrexone
03
Conditions
opioid use disorder (OUD)heroin addiction
Beyond the preview
Go deeper on NL-OMON35900.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON35900.